Detalhe da pesquisa
1.
A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.
Cancer;
121(4): 570-9, 2015 Feb 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25312684
2.
Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma.
Clin Cancer Res;
30(2): 323-333, 2024 01 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38047868
3.
Combined Central Retinal Artery and Vein Occlusion with Ischemic Optic Neuropathy After COVID-19 Vaccination.
Int Med Case Rep J;
15: 7-14, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35079224
4.
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors.
Clin Cancer Res;
27(10): 2723-2733, 2021 05 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33622704
5.
A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1.
Oncoimmunology;
9(1): 1847846, 2020 11 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33312760
6.
Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies.
Expert Opin Investig Drugs;
26(4): 427-443, 2017 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28267385
7.
Review: desmoplastic small round cell tumor: current treatment approach and role of targeted therapy.
Clin Adv Hematol Oncol;
7(7): 476-8, 2009 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19701156
8.
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.
J Clin Oncol;
30(1): 78-84, 2012 01 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22067397
9.
Heat shock proteins: a potential anticancer target.
Curr Drug Targets;
12(14): 2001-8, 2011 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21777196
10.
Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.
Expert Opin Drug Metab Toxicol;
5(12): 1607-14, 2009 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19929449
11.
Future options for imatinib mesilate-resistant tumors.
Expert Opin Investig Drugs;
16(10): 1549-60, 2007 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17922620